A neuromuscular drug candidate acquired by Novartis (NVS) through its $12 billion Avidity Biosciences deal missed its primary endpoint in a late-stage trial, raising fresh questions about the durability of the Swiss drugmaker’s pipeline investments.
The failure compounds investor concern about near-term revenue mix, arriving just days after Novartis also reported that its cardiovascular candidate pelacarsen flopped in the Phase 3 HORIZON trial – two high-profile setbacks within a single week for a company that has staked billions on external pipeline acquisitions. Earlier pipeline turbulence at Novartis has already tested confidence in its autoimmune and specialty pipeline.
Key Takeaways
- Avidity-derived neuromuscular drug misses its late-stage primary endpoint.
- Setback is one of two major trial failures for Novartis in a week.
- $12 billion Avidity deal now faces scrutiny over pipeline returns.
Market Reaction & Context
Novartis shares have faced downward pressure following the twin trial failures, putting NVS at a disadvantage relative to large-cap European pharma peers such as Roche and AstraZeneca, which have each reported positive late-stage data in recent months. The back-to-back setbacks amplify questions about whether the Avidity acquisition price – one of the largest biotech deals of recent years – can be justified by the remaining two candidates in that acquired pipeline. 1
The neuromuscular therapy was one of three assets Novartis absorbed from Avidity, a San Diego-based company specializing in RNA-targeted medicines. With one of those three now eliminated from the development path, the burden of proof on the remaining duo is materially higher.
Detailed Analysis
The pelacarsen cardiovascular failure, reported on September 4, had already signaled that Novartis’s pipeline was under strain. 2 Pelacarsen had shown in earlier studies that it could substantially reduce Lp(a) – a lipid protein linked to elevated cardiovascular risk – but failed to translate that biomarker improvement into a reduction of actual cardiovascular deaths, heart attacks, or strokes in the HORIZON trial. Rivals Amgen and Eli Lilly are continuing their own Lp(a)-lowering programs, potentially filling the commercial void Novartis leaves behind.
The neuromuscular miss is a distinct but equally consequential blow. Neuromuscular diseases represent a high-value therapeutic space, where approved therapies command premium pricing and address underserved patient populations. A Phase 3 failure in this category not only eliminates a potential blockbuster but also signals that the clinical and translational risk embedded in the Avidity assets was higher than the acquisition price implied.
Long-horizon investors tracking pharma pipeline durability will note that Novartis now must rely more heavily on its established franchises – including the heart-failure drug Entresto and the multiple sclerosis therapy Kesimpta – to sustain revenue growth while the pipeline is rebuilt. Analysts had previously flagged that the Avidity acquisition was intended to diversify Novartis away from dependence on those maturing assets.
Outlook & Management Perspective
“The drug candidate was one of three therapies the Swiss pharmaceutical company added to its pipeline through its $12 billion acquisition of Avidity Biosciences,” according to reporting on the trial outcome. 1
Novartis has not yet said publicly whether it will pursue any further development path for the failed neuromuscular candidate, such as a narrowed patient subgroup analysis or a reformulated trial design. The company is expected to address pipeline strategy at its next investor update, where management will face pressure to articulate how the two remaining Avidity assets – and broader pipeline – can compensate for the loss.
Conclusion
Two late-stage failures in less than a week represent a meaningful setback for Novartis’s stated strategy of pipeline-led growth through acquisition. For long-horizon investors weighing the company’s revenue mix over the next five years, the central question is whether the remaining Avidity assets and other mid-stage candidates carry enough probability-adjusted value to offset the $12 billion commitment. Until Novartis provides updated guidance on its pipeline priorities, investors are likely to demand a wider risk discount on the stock’s pipeline premium.
Not investment advice. For informational purposes only.
References
1(2026-09-08). “Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial”. The Wall Street Journal. Retrieved September 8, 2026.
2Andrew Joseph (September 4, 2026). “Novartis’ experimental cardiovascular drug fails a pivotal study”. STAT News. Retrieved September 8, 2026.